ArticleMalaria journal2025
Field trial finds promising evidence on Spinosad: a bio-larvicide for mosquito control in urban settings in Bengaluru, India.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMosquitoes are primary vectors for various diseases, with urban areas particularly vulnerable due to dense populations and favourable breeding conditions. In India, mosquito-borne diseases such as malaria, dengue, and lymphatic filariasis remain pressing public health concerns. This study assessed the effectiveness and longevity of Spinosad, a naturally derived bio-larvicide, as an eco-friendly alternative to conventional insecticides.
methodsA large-scale field study, following WHO protocols, tested three Spinosad formulations - DT (7.48%), EC (20.6%), and G30 (2.5%) against Aedes aegypti and Anopheles stephensi. EC (2.5%) and G30 were also tested against Culex quinquefasciatus across seasons. Reapplication was performed when immature-mosquito densities in treated sites matched those in controls.
resultsAll formulations documented rapid and significant immature-mosquito densities reduction. Efficacy duration varied by formulation, species, and habitat: reapplication for Aedes, was required on day 28(EC), day 35(G30) and day 56(DT) (P = 0.104); for Anopheles, on day 52.5 (53)(EC), day 49(G30) & day 70(DT) (P = 0.736); for Culex, on day 35(EC, G30) in drains and day 49(G30) or day 63(EC) in cement tanks (p = 0.896).
conclusionThe study underscores Spinosad's strong larvicidal effect at low dosages, significantly outperforming conventional larvicides. In the context of rising insecticide resistance and recurring disease outbreaks, Spinosad is an effective, and sustainable tool for mosquito larval control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.